JP2006141398A5 - - Google Patents

Download PDF

Info

Publication number
JP2006141398A5
JP2006141398A5 JP2005347888A JP2005347888A JP2006141398A5 JP 2006141398 A5 JP2006141398 A5 JP 2006141398A5 JP 2005347888 A JP2005347888 A JP 2005347888A JP 2005347888 A JP2005347888 A JP 2005347888A JP 2006141398 A5 JP2006141398 A5 JP 2006141398A5
Authority
JP
Japan
Prior art keywords
recombinant ndv
recombinant
ndv
heterologous gene
immunostimulatory protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005347888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006141398A (ja
Filing date
Publication date
Priority claimed from EP98202054A external-priority patent/EP0974660A1/en
Application filed filed Critical
Publication of JP2006141398A publication Critical patent/JP2006141398A/ja
Publication of JP2006141398A5 publication Critical patent/JP2006141398A5/ja
Pending legal-status Critical Current

Links

JP2005347888A 1998-06-19 2005-12-01 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ Pending JP2006141398A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98202054A EP0974660A1 (en) 1998-06-19 1998-06-19 Newcastle disease virus infectious clones, vaccines and diagnostic assays

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000554854A Division JP2002518012A (ja) 1998-06-19 1999-06-17 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009023349A Division JP2009261387A (ja) 1998-06-19 2009-02-04 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Publications (2)

Publication Number Publication Date
JP2006141398A JP2006141398A (ja) 2006-06-08
JP2006141398A5 true JP2006141398A5 (enExample) 2006-08-03

Family

ID=8233832

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000554854A Withdrawn JP2002518012A (ja) 1998-06-19 1999-06-17 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ
JP2005347888A Pending JP2006141398A (ja) 1998-06-19 2005-12-01 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ
JP2009023349A Pending JP2009261387A (ja) 1998-06-19 2009-02-04 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000554854A Withdrawn JP2002518012A (ja) 1998-06-19 1999-06-17 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009023349A Pending JP2009261387A (ja) 1998-06-19 2009-02-04 ニューカッスル病ウイルス感染性クローン、ワクチンおよび診断アッセイ

Country Status (28)

Country Link
US (3) US6719979B2 (enExample)
EP (2) EP0974660A1 (enExample)
JP (3) JP2002518012A (enExample)
KR (1) KR20010053000A (enExample)
CN (2) CN101275142A (enExample)
AR (1) AR020091A1 (enExample)
AT (1) ATE367442T1 (enExample)
AU (1) AU754844B2 (enExample)
BR (1) BR9911383A (enExample)
CA (1) CA2334165A1 (enExample)
CZ (1) CZ300760B6 (enExample)
DE (1) DE69936585T2 (enExample)
DK (1) DK1088077T3 (enExample)
EA (1) EA004796B1 (enExample)
ES (1) ES2291029T3 (enExample)
HR (1) HRP20010042B1 (enExample)
HU (1) HUP0102429A3 (enExample)
ID (1) ID27343A (enExample)
IL (2) IL140381A0 (enExample)
NO (1) NO329193B1 (enExample)
NZ (1) NZ508982A (enExample)
PL (1) PL197722B1 (enExample)
PT (1) PT1088077E (enExample)
SI (1) SI1088077T1 (enExample)
TR (1) TR200100350T2 (enExample)
UA (1) UA77146C2 (enExample)
WO (1) WO1999066045A1 (enExample)
ZA (1) ZA200100241B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US10383936B2 (en) * 1999-05-05 2019-08-20 University Of Maryland, College Park Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector
US7244558B1 (en) * 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
EP1074614B1 (en) * 1999-07-27 2004-07-07 Akzo Nobel N.V. A recombinant Newcastle disease virus for in ovo vaccination
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
ATE437223T1 (de) * 2000-06-23 2009-08-15 Intervet Int Bv Attenuiertes bovines respiratorisches syncytialvirus
ATE352557T1 (de) 2000-11-02 2007-02-15 Intervet Int Bv Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
KR100437888B1 (ko) * 2001-07-30 2004-07-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
DE60114420T2 (de) * 2001-10-04 2006-07-13 Centrum Voor Onderzoek In Diergeneeskunde En Agrochemie Abgeschwächter Mutantenstamm eines Virus der Newcastle-Krankheit für eine in Ovo Impfung und dessen Benutzung
JP2005518209A (ja) * 2002-02-21 2005-06-23 マウント シナイ スクール オブ メディシン 組換えマイナス鎖ウイルスrna発現系およびワクチン
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
US7132291B2 (en) 2003-05-05 2006-11-07 Dow Agro Sciences Llc Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
AU2004235800B2 (en) * 2003-05-05 2010-02-18 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
CA2503774C (en) 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
US7527638B2 (en) 2003-12-16 2009-05-05 Depuy Spine, Inc. Methods and devices for minimally invasive spinal fixation element placement
MY146476A (en) 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
KR20090007706A (ko) * 2006-03-15 2009-01-20 인터벳 인터내셔널 비.브이. 조류 인플루엔자 바이러스의 h5 헤마글루티닌을 발현하는 재조합 뉴캐슬병 바이러스
AU2007226555B2 (en) * 2006-03-15 2012-07-05 Intervet International B.V. Recombinant Mononegaviral virus vectors
KR100776398B1 (ko) * 2006-03-23 2007-11-28 주식회사 고려비엔피 조류 hn 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스
KR100801180B1 (ko) 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
KR100874256B1 (ko) 2007-02-12 2008-12-16 대한민국 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도
KR100955502B1 (ko) * 2007-11-30 2010-04-30 대한민국 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US7794714B2 (en) * 2008-03-14 2010-09-14 The United States Of America As Represented By The Secretary Of Agriculture Newcastle disease virus monoclonal antibodies
US20090258035A1 (en) * 2008-03-21 2009-10-15 The United States Of America, As Represented By The Secretary Of Agriculture Avian virus vaccines and uses thereof
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
MX2012002114A (es) 2009-08-21 2012-08-08 Univ Georgia Vacuna de paramixovirus aviar recombinante y metodo para hacerla y usarla.
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
JP6293664B2 (ja) 2011-10-27 2018-03-14 ウェルスタット オフサルミクス コーポレイション 桿体由来錐体生存因子をコードするベクター
WO2013082327A1 (en) 2011-11-30 2013-06-06 Merial Limited Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 hn 단백질 및 이를 포함하는 hi법 검사용 항원진단액
WO2014158811A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
CN104059942B (zh) * 2013-03-20 2016-12-28 湖北省农业科学院畜牧兽医研究所 新城疫病毒耐热活疫苗载体系统及其应用
US20140341950A1 (en) * 2013-05-15 2014-11-20 University Of Georgia Research Foundation, Inc. Recombinant avian paramyxovirus vaccine and method for making and using thereof
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
US10780158B2 (en) 2015-11-16 2020-09-22 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
RU2769406C2 (ru) 2016-02-03 2022-03-31 СиДжи ДИСКАВЕРИ, ИНК. Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
MX2020008988A (es) * 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
WO2020014591A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
CN109735552A (zh) * 2019-02-27 2019-05-10 苏州世诺生物技术有限公司 禽新城疫病毒新型基因工程亚单位疫苗
CN110018304A (zh) * 2019-05-15 2019-07-16 河南省农业科学院 一种新城疫抗体阻断检测试纸
CN110240635B (zh) * 2019-06-10 2022-04-22 华中农业大学 检测新城疫病毒抗体的多肽及其elisa检测试剂盒
CN110257562A (zh) * 2019-07-31 2019-09-20 河北农业大学 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用
US11334671B2 (en) * 2019-10-14 2022-05-17 International Business Machines Corporation Adding adversarial robustness to trained machine learning models
KR102154796B1 (ko) * 2019-10-18 2020-09-22 주식회사 바이오포아 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
CN110938711A (zh) * 2019-12-20 2020-03-31 河北农业大学 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法
CN111334528B (zh) * 2020-03-20 2022-02-18 山东农业大学 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用
CN112048484A (zh) * 2020-07-27 2020-12-08 华南农业大学 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN114214338B (zh) * 2021-08-26 2023-02-03 扬州大学 猪源piv5全长感染性克隆及其制备方法和应用
WO2024206928A1 (en) 2023-03-30 2024-10-03 Pharma Cinq, Llc VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
EP0832197A4 (en) * 1995-06-07 2002-10-16 Syntro Corp RECOMBINANT AVIAN SMALLPOX VIRUS AND USES THEREOF
ATE181112T1 (de) * 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines

Similar Documents

Publication Publication Date Title
JP2006141398A5 (enExample)
Masihi Fighting infection using immunomodulatory agents
JP2008529558A5 (enExample)
JP2018523668A5 (enExample)
JP2005530716A5 (enExample)
JP2019506175A5 (enExample)
JP2008530245A5 (enExample)
BRPI0111639B1 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
JP2005237328A5 (enExample)
JP6300827B2 (ja) ケイ化ウイルスを含む免疫原性組成物および使用の方法
JP2005533491A (ja) 免疫賦活オリゴヌクレオチド及びその使用
JP2017524682A5 (enExample)
JP2005511076A5 (enExample)
JP2007523863A5 (enExample)
JP2002542827A5 (enExample)
MY131143A (en) Proteins derived from white spot syndrome virus and uses thereof
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
JP2022078067A5 (enExample)
JP2014519817A5 (enExample)
JP2010508857A5 (enExample)
JP2005512518A5 (enExample)
JP2006502228A5 (enExample)
WO2001004280A3 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
JP2005526520A5 (enExample)
Krieg The CpG motif: implications for clinical immunology